|
Çѱ¹Organon |
Çѱ¹Organon-Market Access Specialist 1¸í ¸ðÁý
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
12.04 |
|
|
½«Ä¿ÄÚ¸®¾Æ |
Healthcare Quality Management(Pharmacist)
°æ±â ±ºÆ÷½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
05.20 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
PV Contract ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.10 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
[Çѱ¹MSD]RA Specialist ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
06.07 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD RA Specialist Á¤±ÔÁ÷ ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
05.31 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Diabetes Medical Lead
¼¿ï ¼Ãʱ¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.29 |
|
|
(ÁÖ)¼Æ펾àÇ° |
ÀǾàÇ°¼öÀÔ, ¾ÈÀü°ü¸®/Çã°¡ ¾à»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.28 |
|
|
½ÌÅ©ÅÊÅ©(ÁÖ) |
¿Ü±¹°èÁ¦¾àȸ»ç ÀÓ»ó±âȹ °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
02.15 |
|
|
(ÁÖ)¸ÞµðÄÄÀεñ½º |
Medical communication program ¹× contents °³¹ß
¼¿ï °³²±¸ | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
11.21 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Market access(Price&reimburse)specialist ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
±¤°í/È«º¸/PR/»çº¸ |
3³â¡è |
ä¿ë½Ã |
10.29 |
|
|
DOCS ICON Resourcing Solutions |
¿Ü±¹°è CRO-Study Authorization Associate (1¸í)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
09.23 |
|
|
DOCS ICON Resourcing Solutions |
¿Ü±¹°è CRO- Jr. CRA (5¸í ä¿ë)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
09.21 |
|
|
À¯»ó±×¸°ÄɹÌÄÃÄÚ¸®¾Æ(ÁÖ) |
¾à»ç¸¦ ¸ðÁýÇÕ´Ï´Ù
¼¿ï ÀüÁö¿ª, °æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.28 |
|
|
¾Ëº¸Á¨ ÄÚ¸®¾Æ |
Á¦Á¶°ü¸® ¾à»ç ¸ðÁý(ÆÄƮŸÀÓ/°æ·Â¹«°ü)
°æ±â ȼº½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.12 |
|
|
Logis Pharm |
KGSP Ç°Áú°ü¸® ¾à»ç´ÔÀ» ¸ð½Ê´Ï´Ù
°æ±â ÀÌõ½Ã | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
08.27 |
|